-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on LENZ Therapeutics, Lowers Price Target to $50

Benzinga·10/21/2026 14:59:19
Listen to the news
TD Cowen analyst Stacy Ku maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $60 to $50.